Opinion on R&D in Europe

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Novartis: good results from three Lotrel trials

Lotrel demonstrated positive results in various hard-to-treat hypertensive patient groups. This places Novartis' drug in an advantageous position compared to the market leading single compound antihypertensive, Pfizer's Norvasc. If forthcoming trial results in African-Americans prove similarly positive, the drug's sales should be stronger still.

Published By Datamonitor
17 May 2002
CommentWire
CommentWire

Novartis: Glivec leaves Brits unconvinced

Despite Novartis' chronic myeloid leukemia drug Glivec gaining fast-track approval in Europe, NICE has decided to limit its use in CML patients to the accelerated phase only. The watchdog's reason was the lack of cost-effective data, showing that pharma companies need to ensure their clinical trials highlight this factor convincingly.

Published By Datamonitor
15 May 2002
CommentWire
CommentWire

Norwich Union: pay-as-you-motor insurance

Using the latest technology devices, Norwich Union is piloting a new method of calculating premiums. The 'pay-as-you-go' Autograph system claims to have lowered motor insurance in the US, but many UK drivers may find that they are better off under the traditional system.<BR /><BR /><BR />

Published By Datamonitor
26 Feb 2002
CommentWire
CommentWire

Norwich Union: online boost for UK commercial brokers

The project, known as CMLP, should cut the costs associated with policy issuing significantly. It may also improve Norwich Union's relations with its brokers, which have been somewhat strained over the last couple of years. If successful, it is likely to lead other UK insurers to develop their own platforms - bad news for insurance eBusiness vendors.

Published By Datamonitor
11 Dec 2001
CommentWire
CommentWire

NicOx/AstraZeneca: NO-Naproxen announcement stuns partner

Hopes for the leading compound in the CINOD class of arthritis drugs have been dealt a serious blow after it failed to live up to expectations in phase II trials. AstraZeneca may now pull out of its partnership with the drug's developer, NicOx. Although great things had been anticipated for the drug, it now seems highly unlikely that it will challenge the leading COX-II inhibitors.

Published By Datamonitor
28 Feb 2003
CommentWire
CommentWire

NicOx/AstraZeneca: a new class of pain medication

NicOx's HCT 3012 is a new class of analgesic and anti-inflammatory drug, with a superior gastrointestinal safety profile compared to naproxen. With AstraZeneca's backing, this product has the marketing strength to compete with Pharmacia and Merck - who currently dominate the non steroidal anti inflammatory drugs (NSAID) market.

Published By Datamonitor
23 May 2002
Expert View
Expert View

Multiple Sclerosis: the search for a vaccine continues

There are approximately 250,000 to 350,000 diagnosed cases of multiple sclerosis in the US, yet it is estimated that the actual number of Americans with MS may be even higher. As a new approach to the treatment of MS, vaccines have the potential to be both efficacious and cost effective. But can a vaccine be developed as a viable treatment for MS?

Published By Datamonitor
02 Aug 2002
CommentWire
CommentWire

Multiple sclerosis: more trials in the UK

The long-running debate over reimbursement of the beta-interferon class is set to enter a new stage. NICE and the pharma companies will conduct a long-term trial with a view to establishing, once and for all, the benefits this treatment confers, and whether they justify the huge cost. The outcome could be positive for pharma companies, but a final decision will be years away.

Published By Datamonitor
01 Nov 2001
CommentWire
CommentWire

MorphoSys/Roche: antibody hopes for Alzheimer's

German biotech MorphoSys and its partner Roche have achieved a key milestone in discovering a series of antibodies to treat CNS disorders such as Alzheimer's disease. While there are still serious technical and clinical challenges ahead, this innovative new development is certainly good news for Europe's biotechnology sector.

Published By Datamonitor
10 Jul 2002
Expert View
Expert View

MMR: controversy puts the Government under pressure

After hearing about a possible link with autism many parents are refusing to allow doctors to give their children the MMR vaccine. As a result, the number of measles cases in the UK has risen dramatically. Datamonitor's Oliver Luft outlines the series of events that led to the current crisis and investigates whether or not the government can encourage more parents to take up the combined vaccine.

Published By Datamonitor
12 Jul 2002

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.